{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:34:11Z","timestamp":1792517651611,"version":"4.5.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Results of 2 parallel phase 2 trials of transplantation of unrelated umbilical cord blood (UCB) or bone marrow (BM) from HLA-haploidentical relatives provided equipoise for direct comparison of these donor sources. Between June 2012 and June 2018, 368 patients aged 18 to 70 years with chemotherapy-sensitive lymphoma or acute leukemia in remission were randomly assigned to undergo UCB (n = 186) or haploidentical (n = 182) transplant. Reduced-intensity conditioning comprised total-body irradiation with cyclophosphamide and fludarabine for both donor types. Graft-versus-host disease prophylaxis for UCB transplantation was cyclosporine and mycophenolate mofetil (MMF) and for haploidentical transplantation, posttransplant cyclophosphamide, tacrolimus, and MMF. The primary end point was 2-year progression-free survival (PFS). Treatment groups had similar age, sex, self-reported ethnic origin, performance status, disease, and disease status at randomization. Two-year PFS was 35% (95% confidence interval [CI], 28% to 42%) compared with 41% (95% CI, 34% to 48%) after UCB and haploidentical transplants, respectively (P = .41). Prespecified analysis of secondary end points recorded higher 2-year nonrelapse mortality after UCB, 18% (95% CI, 13% to 24%), compared with haploidentical transplantation, 11% (95% CI, 6% to 16%), P = .04. This led to lower 2-year overall survival (OS) after UCB compared with haploidentical transplantation, 46% (95% CI, 38-53) and 57% (95% CI 49% to 64%), respectively (P = .04). The trial did not demonstrate a statistically significant difference in the primary end point, 2-year PFS, between the donor sources. Although both donor sources extend access to reduced-intensity transplantation, analyses of secondary end points, including OS, favor haploidentical BM donors. This trial was registered at www.clinicaltrials.gov as #NCT01597778.<\/jats:p>","DOI":"10.1182\/blood.2020007535","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T08:38:26Z","timestamp":1598949506000},"page":"420-428","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":209,"title":["Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-6924","authenticated-orcid":false,"given":"Ephraim J.","family":"Fuchs","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Eapen","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Logan","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Department of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dawson","sequence":"additional","affiliation":[{"name":"Emmes Corporation, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Devine","sequence":"additional","affiliation":[{"name":"National Marrow Donor Program, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatchada","family":"Karanes","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematopoietic Cell Transplantation (HCT), City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leifer","sequence":"additional","affiliation":[{"name":"Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Magenau","sequence":"additional","affiliation":[{"name":"Michigan Medicine Bone Marrow Transplant and Leukemia, C. S. Mott Children\u2019s Hospital, University of Michigan, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, KS;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence E.","family":"Morris","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University Medical Center, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1997-3799","authenticated-orcid":false,"given":"Claudio G.","family":"Brunstein","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2021012116220047400_B1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.1997.15.5.1767","article-title":"Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings","volume":"15","author":"Szydlo","year":"1997","journal-title":"J Clin Oncol"},{"issue":"13","key":"2021012116220047400_B2","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2021012116220047400_B3","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2004-07-2717","article-title":"Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy","volume":"105","author":"Barker","year":"2005","journal-title":"Blood"},{"issue":"22","key":"2021012116220047400_B4","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2010-05-285304","article-title":"Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood","volume":"116","author":"Brunstein","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2021012116220047400_B5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nrclinonc.2015.234","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2021012116220047400_B6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2021012116220047400_B7","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.bbmt.2014.05.015","article-title":"Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies","volume":"20","author":"Eapen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"282","key":"2021012116220047400_B8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2021012116220047400_B9","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Stat"},{"issue":"2","key":"2021012116220047400_B10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Methodol"},{"issue":"8","key":"2021012116220047400_B11","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2021012116220047400_B12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2019.10.014","article-title":"Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-haploidentical related stem cell transplantation for adults with hematologic malignancies","volume":"26","author":"Sanz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2021012116220047400_B13","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.bbmt.2016.06.012","article-title":"Infection rates among acute leukemia patients receiving alternative donor hematopoietic cell transplantation","volume":"22","author":"Ballen","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2021012116220047400_B14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2017014464","article-title":"Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD","volume":"2","author":"Bejanyan","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"2021012116220047400_B15","first-page":"443","article-title":"Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion","volume":"7","author":"Ash","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2021012116220047400_B16","doi-asserted-by":"crossref","first-page":"e86252","DOI":"10.1172\/jci.insight.86252","article-title":"Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide","volume":"1","author":"Kanakry","year":"2016","journal-title":"JCI Insight"},{"issue":"11","key":"2021012116220047400_B17","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"2021012116220047400_B18","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/bloodadvances.2018021980","article-title":"Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity","volume":"2","author":"Eapen","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2021012116220047400_B19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2021012116220047400_B20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbmt.2013.01.016","article-title":"Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies","volume":"19","author":"Gladstone","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2021012116220047400_B21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.bbmt.2017.03.001","article-title":"Prospective evaluation of unrelated donor cord blood and haploidentical donor access reveals graft availability varies by patient ancestry: practical implications for donor selection","volume":"23","author":"Kosuri","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2021012116220047400_B22","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.19.02408","article-title":"Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR","volume":"38","author":"Fatobene","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/3\/420\/1798112\/bloodbld2020007535.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/3\/420\/1798112\/bloodbld2020007535.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T19:54:30Z","timestamp":1723492470000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/3\/420\/463595\/Double-unrelated-umbilical-cord-blood-vs-HLA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,1,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020007535","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738597150.793580649","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]}}}